Image Place holder

Celeste Bello, MD


Specialty: Hematology/Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Focus: Hodgkin Lymphoma , Leukemia , Non-Hodgkin Lymphoma

Dr. Celeste Bello is a double board-certified hematologist and medical oncologist at Moffitt Cancer Center. She joined the faculty at Moffitt Cancer Center in 2008 after completing her fellowship at the University of South Florida. Dr. Bello has developed special expertise in managing patients with Hodgkin’s and non-Hodgkin’s lymphomas, a special category within the broader group of hematologic (blood) malignancies. Examples of non-Hodgkin’s lymphomas include follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. She is a current member of the National Comprehensive Cancer Network Hodgkin lymphoma guidelines panel. She also specializes in treating patients with central nervous system lymphomas. Dr. Bello is an active researcher in the field and can often offer her patients several options for clinical trials in addition to the standard therapies. She is very involved with the education of medical students and residents at the University of South Florida and at Moffitt Cancer Center. She is also a frequent lecturer on lymphomas for both medical and lay audiences, including presenting at Lymphoma Research Foundation events.

Education & Training

Board Certification:

  • Medical Oncology
  • Hematology

Fellowship:

  • University of South Florida - Hematology/Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • University of South Florida - MD
Participating Trials

CLINICAL TRIAL 18744
A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Condition: Malignant Hematology
Intervention: MEDI-570
Open

CLINICAL TRIAL 19341
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Condition: Immunotherapy
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; MESNA; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19392
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients with Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
Condition: Malignant Hematology
Intervention: BNZ-1
Open

CLINICAL TRIAL 19482
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: CPX-351 (Vyxeos); Vyxeos; methotrexate
Open

CLINICAL TRIAL 19629
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Brutons Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies
Condition: Malignant Hematology
Intervention: SNS-062 (Vecabrutinib)
Open

CLINICAL TRIAL 19584
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Condition: Malignant Hematology
Intervention: INCB050465; Not Applicable
Open

CLINICAL TRIAL 19725
A Phase 1/2 Multicenter Study Evaluating the Safety And Efficacy Of Axicabtagene Ciloleucel in Combination with Utomilumab in Subjects with Refractory Large B-Cell Lymphoma (Zuma-11)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); PF-05082566 (utomilumab); utomilumab
Open

CLINICAL TRIAL 19390
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Condition: Malignant Hematology
Intervention: E7777
Open

CLINICAL TRIAL 19721
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19637
A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients with Hyperglycemia
Condition: Multiple
Intervention: Insulin
Open

CLINICAL TRIAL 19199
Phase II Trial of Ibrutinib and PD-1 Blockade in High Risk Chronic Lymphocytic Leukemia to Improve Immune Function.
Condition: Malignant Hematology
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19812
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19829
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Condition: Malignant Hematology
Intervention: PBCAR0191; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19070
Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel or the Treatment of Subjects with Relapsed/Refractory Large B-Cell Lymphoma
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19719
A Phase Ib, Multicenter Study To Determine The Safety And Tolerability of Tisagenlecleucel in Combination with Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Condition: Malignant Hematology
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Tisagenlecleucel
Open

CLINICAL TRIAL 19715
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: Adriamycin (doxorubicin); Bendamustine; Mosunetuzumab; Obinutuzumab; Polatuzumab Vedotin; R-CHOP; R-CVP; Rituxan (rituximab); Tocilizumab; Vincristine; cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; prednisone; rituximab
Open

CLINICAL TRIAL 19729
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Condition: Malignant Hematology
Intervention: Cobomarsen; SAHA (Vorinostat); Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 20069
A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)
Condition: Malignant Hematology
Intervention: CC-99282; Rituxan (rituximab); rituximab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Mirza AS, Dholaria BR, Hussaini M, Mushtaq S, Horna P, Ravindran A, Kumar A, Ayala E, Kharfan-Dabaja MA, Bello C, Chavez JC, Sokol L. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Mar;19(9):e513-e520. Pubmedid: 31253594.
  • Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019 Jun;134(7):606-613. Pubmedid: 31186274.
  • Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. J Natl Compr Canc Ne. 2018 Mar;16(3):245-254. Pubmedid: 29523663.
  • Abuodeh Y, Ahmed K, Echevarria M, Naghavi A, Grass GD, Robinson TJ, Tomblyn M, Shah B, Chavez J, Bello C, El-Haddad G, Harrison L, Kim S. Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Ther Adv Hematol. 2017 Apr;8(4):129-138. Pubmedid: 28491264. Pmcid: PMC5405899.
  • Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B. Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S170-S174. Pubmedid: 27521314.
  • Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H. Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Ne. 2015 May;13(5):554-586. Pubmedid: 25964641. Pmcid: PMC4898052.
  • Eatrides J, Thompson Z, Lee JH, Bello C, Dalia S. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Ann Hematol. 2015 Feb;94(2):357-358. Pubmedid: 25034876.
  • Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb;125(9):1394-1402. Pubmedid: 25573987.
  • Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May;123(22):3390-3397. Pubmedid: 24615777. Pmcid: PMC4123414.
  • Trimaldi JA, Bowers JW, Bello C, Sagatys EM. Follicular lymphoma with progression to diffuse large B-cell lymphoma and concurrent CD5-negative mantle cell lymphoma-3 entities in a lymph node. Cancer Control. 2014 Jul;21(3):251-254. Pubmedid: 24955711.
  • Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014 Aug;93(8):1305-1312. Pubmedid: 24590536.
  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr;38(4):443-446. Pubmedid: 24439565.
  • Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr;99(4):450-456. Pubmedid: 24584873.
  • Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible?. Leuk Res Treatment. 2013 Nov;2013:629283. Pubmedid: 24288618. Pmcid: PMC3833187.
  • Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Ne. 2012 May;10(5):589-597. Pubmedid: 22570290.
  • Bello C, Sokol L. B-cell non-hodgkin lymphoma: targeting in on the future. Cancer Control. 2012 Jul;19(3):171-172. Pubmedid: 22710892.
  • Bello C, Zhang L, Naghashpour M. Follicular lymphoma: current management and future directions. Cancer Control. 2012 Jul;19(3):187-195. Pubmedid: 22710894.
  • Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J. Hodgkin lymphoma. J Natl Compr Canc Ne. 2011 Sep;9(9):1020-1058. Pubmedid: 21917626.
  • Bello C, Veliz M, Pinilla-Ibarz J. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Expert Rev Clin Immunol. 2011 May;7(3):295-300. Pubmedid: 21595596.
  • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.
  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.
  • Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011 Apr;117(7):1463-1469. Pubmedid: 21425147. Pmcid: PMC4545502.
  • Pinilla-Ibarz J, Bello C. Modern approaches to treating chronic myelogenous leukemia. Curr Oncol Rep. 2008 Sep;10(5):365-371. Pubmedid: 18706263.